25.10.2012 - Fujifilm Diosynth has partnered with British Piramal Healthcare to produce Antibody Drug Conjugates.
Fujifilm Diosynth Biotechnologies has entered into a strategic alliance with Piramal Healthcare UK Ltd (Billingham, UK) in the emerging market of antibody drug conjugates (ADCs), that is antibodies chemically coupled to a small molecule toxin. Under the terms of the contract development and manufacture agreement, Piramal will bring in its expertise in antibody drug conjugation while Fujifilm Diosynth Biotechnologies will provide its experience in manufacturing biopharmaceuticals in mammalian cell culture. The companies said the deal will allow customers to benefit from the experience and assets of both organisations, while simplifying the supply chain and vendor management relationships, leading to shorter time to clinic.
The partnership covers work on more than 150 biopharmaceuticals and over 300 batches of ADCs spanning over more than 30 different NCEs, including the world's only FDA-approved ADC, Seattle Genetics’ Adcetris. Fujifilm Diosynth Biotechnologies recently announced an expansion of its cGMP manufacturing facilities at both its RTP, USA and Billingham, UK sites.
04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.
03.07.2014 Nicox S.A. is stretching beyond the European market: The French eye health specialist is set to acquire Aciex Therapeutics Inc., a US-based pharma company with several ophthalmic therapeutics nearing market maturity.